{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-008409","form_type":"8-K","ticker":"LNSR","cik":"0001320350","company_name":"LENSAR, Inc.","filed_at":"2022-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.903882+00:00","generated_at":"2026-06-27T01:53:45.039229+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"LENSAR Q4 2021 revenue $11.2M (+35% YoY); full-year revenue up 31% to $34.2M; net loss narrows","bullets":["Q4 revenue $11.2M vs $8.3M YoY; full-year revenue $34.2M (+31% vs 2020).","Net loss $3.9M ($0.41 per share) vs $6.8M ($0.78) in Q4 2020; loss narrowed.","Procedure volume up 37% in Q4 and 35% for full year 2021.","ALLY Adaptive Cataract Treatment System 510(k) submitted and accepted for FDA substantive review.","Cash of $31.6M with only $0.7M used in Q4; commercial launch of ALLY expected in 2022 subject to FDA clearance."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-008409","json":"https://secwatch.observer/filing/0001564590-22-008409.json","markdown":"https://secwatch.observer/filing/0001564590-22-008409.md","text":"https://secwatch.observer/filing/0001564590-22-008409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000156459022008409/0001564590-22-008409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000156459022008409/lnsr-8k_20220303.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:53:45.039229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}